PALI
$1.89-0.12 (-5.74%)
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases.
Recent News
Palisade Bio (PALI) Reports Positive Phase 1b Data for PALI-2108 in UC Patients
Palisade Bio Inc. (NASDAQ:PALI) is one of the best growth stocks to buy right now. On February 23, Palisade Bio presented translational data from its Phase 1b study of PALI-2108. The findings highlight that this once-daily oral prodrug, designed for targeted delivery to the terminal ileum and colon, achieved localized target engagement and clinical response […]
Palisade Bio Details PALI-2108 UC, Crohn’s Plans and Cash Runway Into 2029 at Oppenheimer Conference
Palisade Bio (NASDAQ:PALI) executives outlined the company’s strategic pivot, lead development priorities, and financing position during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference. Company background and strategic pivot Chief Executive Officer J.D. Finley said
Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More
Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower on Friday, with the venerable S&P 500 taking early bows as it hit a fresh all-time high, joining the Dow Jones Industrial Average ... Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More
Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results
We recently published 10 Stocks Lighting Up Market Ahead of Christmas. Palisade Bio Inc. (NASDAQ:PALI) is one of the best performers on Wednesday. Palisade extended its winning streak to a fourth straight day on Wednesday, jumping 5.26 percent to close at $2.20 apiece as investors loaded portfolios ahead of the results of its clinical trial […]
Palisade Bio (PALI) Upgraded to Buy: Here's What You Should Know
Palisade Bio (PALI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.